Combining immunotherapy with chemotherapy for non-small cell lung cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase III ALCHEMIST trial investigates the effectiveness of adding pembrolizumab, an immunotherapy drug, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer that has been surgically removed. The study aims to compare disease-free survival and overall survival rates between patients receiving the combination treatment and those receiving chemotherapy alone. Additionally, it evaluates the rates of adverse events and the impact on patients' quality of life. The trial includes various chemotherapy agents and assesses their effectiveness when combined with immunotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* A female of childbearing potential is a sexually mature female who:

  * Has not undergone a hysterectomy or bilateral oophorectomy; or
  * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
* Local testing of EGFR with no EGFR exon 19 deletion or EGFR L858 R mutation (applicable to non-squamous patients only)
* Local testing of ALK with no ALK rearrangement (failed testing is considered negative) (applicable to non-squamous patients only)
* Local testing of PD-L1 immunohistochemistry (IHC) using one of the following assays: DAKO 22C3, DAKO 28-8, EIL3N or SP263
* Completely resected stage IIA, IIB IIIA or IIIB (T3-4N2) non-small cell lung cancer (NSCLC) (squamous or non-squamous) with negative margins (complete R0 resection). Patients will be staged according to the 8th edition of the American Joint Committee on Cancer (AJCC) Staging Manual, 2017

  * Note: Patients with pathologic N2 disease, completely resected, are eligible. However, patients known to have N2 disease prior to surgery are not eligible; guidelines do not recommend up-front surgery for this population
* Complete recovery from surgery. Registration to A081801 must be 30-77 days following surgery
* No prior neoadjuvant or adjuvant therapy for current lung cancer diagnosis
* No prior allogeneic tissue/solid organ transplant
* Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
* No current pneumonitis or history of (non-infectious) pneumonitis that required steroids
* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
* Age \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0-1
* No active auto-immune disease that has required systemic treatment within the last 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment
* Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects

  * Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 7 days prior to registration is required
* No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 3 years. Participants with non-melanoma skin cancers, low grade or low-risk cancers, or stage I malignancies not requiring systemic therapy (e.g., prostate cancer requiring only observation or superficial bladder cancer), or carcinoma in situ (e.g., breast carcinoma or cervical cancer in situ) that have undergone potentially curative therapy are eligible
* No hypersensitivity (\>= grade 3) to pembrolizumab and/or any of its excipients
* No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed
* No known hepatitis C virus (defined as HCV ribonucleic acid \[RNA\] \[qualitative\] is detected) infection or known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive)
* Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* Platelet count \>= 100,000/mm\^3
* Hemoglobin \>= 8 gm/dl
* Calculated (Calc.) creatinine clearance \>= 45 mL/min
* Total bilirubin =\< 1.5 x upper limit of normal (ULN)
* Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN)

Where it's running

• Katmai Oncology Group
  Anchorage, Alaska, United States Recruiting
• Fairbanks Memorial Hospital
  Fairbanks, Alaska, United States Recruiting
• NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
  Jonesboro, Arkansas, United States Recruiting
• Kaiser Permanente-Anaheim
  Anaheim, California, United States Recruiting
• Kaiser Permanente-Deer Valley Medical Center
  Antioch, California, United States Recruiting
• Sutter Auburn Faith Hospital
  Auburn, California, United States Recruiting

+1101 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Jacob M Sands — Alliance for Clinical Trials in Oncology

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using cemiplimab and fianlimab before surgery for non-small cell lung cancer

  This study is testing a combination of two drugs, cemiplimab and fianlimab, before surgery to see if they can help people with stage IB-IIIB non-small cell lung cancer respond better to treatment.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Jacksonville, Florida and 1 other locations · NCT06918132

• Immunotherapy after surgery for early-stage non-small cell lung cancer

  This study is testing if the immunotherapy drug durvalumab can help people with early-stage non-small cell lung cancer stay cancer-free longer after surgery compared to just keeping an eye on them.

  Recruiting at 279 sites Phase 3 National Cancer Institute (NCI) · Jonesboro, Arkansas and 283 other locations · NCT06498635

• Yoga intervention to improve physical performance and quality of life for cancer patients and their caregivers

  This study tests whether a yoga program can help improve physical performance and quality of life for cancer patients and their caregivers during radiotherapy.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT03948100

• Exploring gut microbiome and fecal transplant effects on GI issues in cancer patients

  This study is testing how the gut bacteria affect stomach issues in cancer patients receiving certain treatments and whether a stool transplant can help relieve those problems.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT03819296

• AI-guided radiation therapy for lung tumors

  This study is testing if using artificial intelligence to personalize radiation treatment can help people with lung tumors get better results and reduce the chance of their cancer coming back.

  Recruiting Northwestern University · Chicago, Illinois · NCT05802186

• Using papaverine with chemoradiation to treat advanced non-small cell lung cancer

  This study is testing the best dose of papaverine combined with chemotherapy and radiation to see if it helps people with advanced non-small cell lung cancer live longer and control their tumors better.

  Recruiting at 2 sites Phase 1 Ohio State University Comprehensive Cancer Center · Duarte, California and 1 other locations · NCT05136846

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.